RecruitingMajor Depressive Disorder (MDD)

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

Eligible age

18–65 yrs

Accepts

All genders

Locations

12 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder

Sponsor: Vanda Pharmaceuticals

You may qualify if…

✓ Male or female patient 18 to 65 years of age, inclusive;
✓ Meets DSM-5-TR criteria for MDD
✓ Currently having an inadequate response to antidepressant therapy as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ)

You may not qualify if…

✕ Within the patients lifetime, has a confirmed DSM-5-TR psychiatric diagnosis other than MDD
✕ Within 6 months of Screening, has a confirmed DSM-5-TR psychiatric diagnosis other than MDD
✕ Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment